使用 [(18)F]FLT PET 成像对 AML 患者的治疗反应进行早期评估。
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.
机构信息
Department of Medical Physics, University of Wisconsin, Madison, WI, USA.
出版信息
Leuk Res. 2011 Mar;35(3):310-6. doi: 10.1016/j.leukres.2010.06.010. Epub 2010 Sep 15.
Assessment of treatment response in acute leukemia is routinely performed after therapy via bone marrow biopsy. We investigated the use of positron emission tomography (PET) for early assessment of treatment response in patients with acute myeloid leukemia (AML), using the proliferation marker 3'-deoxy-3'-[(18)F]fluoro-l-thymidine (FLT). Eight adult AML patients receiving induction chemotherapy underwent whole-body FLT PET/CT scans acquired at different time points during therapy. Patients who entered complete remission (CR) exhibited significantly lower FLT uptake in bone marrow than those patients with resistant disease (RD). In bone marrow, mean and maximum standardized uptake values were 0.8, 3.6 for CR and 1.6, 11.4 for RD, p<0.001. FLT PET results for CR and RD patients were independent of assessment time point, suggesting that FLT PET scans acquired as early as 2 days after chemotherapy initiation may be predictive of clinical response. This pilot study suggests that FLT PET imaging during induction chemotherapy may serve as an early biomarker of treatment response in AML.
评估急性白血病的治疗反应通常是在骨髓活检后通过治疗来进行。我们研究了使用正电子发射断层扫描（PET）使用增殖标志物 3'-脱氧-3'-[（18）F]氟代-l-胸苷（FLT）对急性髓细胞性白血病（AML）患者进行早期治疗反应评估。八名接受诱导化疗的成年 AML 患者在治疗过程中不同时间点进行全身 FLT PET/CT 扫描。进入完全缓解（CR）的患者骨髓中的 FLT 摄取明显低于耐药疾病（RD）患者。在骨髓中，平均和最大标准化摄取值分别为 CR 的 0.8 和 3.6，RD 的 1.6 和 11.4，p<0.001。CR 和 RD 患者的 FLT PET 结果与评估时间点无关，这表明在化疗开始后 2 天进行的 FLT PET 扫描可能具有预测临床反应的能力。这项初步研究表明，诱导化疗期间的 FLT PET 成像可能成为 AML 治疗反应的早期生物标志物。
Zotero 插件